Furthermore, SOS1 is essential for the negative feedback regulation of the KRAS pathway; thus, utilizing a combination of KRAS inhibitors and SOS1 inhibitors in KRAS-mutant CRC patients may significantly reverse drug resistance. Here, SOS1 is linked to colorectal carcinoma.